Avidity Biosciences, Inc. (RNA) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	23.5M	18.6M	10.9M	9.6M	9.2M
Cost of Revenue	494.0K	—	—	2.1M	1.4M
Gross Profit	23.0M	18.6M	10.9M	7.5M	7.8M
Operating Expenses
R&D Expense	50.5M	53.8M	303.6M	191.0M	150.4M
SG&A Expense	60.4M	41.7M	86.2M	54.2M	37.7M
General & Admin Expense	36.2M	41.7M	86.2M	54.2M	37.7M
Selling & Marketing Expense	(5.8M)	—	—	—	—
Other Expenses	8.5M	—	—	(2.1M)	(1.4M)
Total Operating Expenses	119.4M	95.4M	389.8M	243.1M	186.8M
Cost and Expenses	119.9M	95.4M	389.8M	245.2M	188.1M
Operating Income (EBIT)	(96.4M)	(76.8M)	(378.9M)	(235.6M)	(178.9M)
Non-Operating
Interest Income	2.1M	—	56.9M	24.0M	5.0M
Interest Expense	—	—	—	—	—
Net Interest Income	2.1M	—	56.9M	24.0M	5.0M
Other Non-Op Income/Expense	3.1M	(12.0K)	56.6M	23.4M	4.9M
Non-Operating Income (excl Interest)	(647.0K)	12.0K	—	—	—
EBT (Pre-Tax Income)	(93.3M)	(76.8M)	(322.3M)	(212.2M)	(174.0M)
Income Tax Expense	(142.0K)	(142.0K)	—	—	—
Bottom Line
Net Income	(93.2M)	(76.7M)	(322.3M)	(212.2M)	(174.0M)
Earnings from Cont. Ops	(93.2M)	(76.7M)	(322.3M)	(212.2M)	(174.0M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(93.2M)	(76.7M)	(322.3M)	(212.2M)	(174.0M)
Per Share
Basic EPS	($3.85)	($4.48)	($2.89)	($2.91)	($3.34)
Diluted EPS	($3.85)	($4.48)	($2.89)	($2.91)	($3.34)
Revenue Per Share	$1.37	$1.09	$0.10	$0.13	$0.18
Shares
Basic Shares Outstanding	17.1M	17.1M	111.6M	73.0M	52.2M
Diluted Shares Outstanding	17.1M	17.1M	111.6M	73.0M	52.2M
Profitability Metrics
EBITDA	(95.1M)	(76.5M)	(376.2M)	(233.5M)	(177.5M)
D&A	685.0K	323.0K	2.8M	2.1M	1.4M
EBIT	(95.7M)	(76.8M)	(378.9M)	(235.6M)	(178.9M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026